JP2009517381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517381A5 JP2009517381A5 JP2008542245A JP2008542245A JP2009517381A5 JP 2009517381 A5 JP2009517381 A5 JP 2009517381A5 JP 2008542245 A JP2008542245 A JP 2008542245A JP 2008542245 A JP2008542245 A JP 2008542245A JP 2009517381 A5 JP2009517381 A5 JP 2009517381A5
- Authority
- JP
- Japan
- Prior art keywords
- uch
- inhibitor
- cancer metastasis
- composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 claims 21
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 claims 18
- OPQRFPHLZZPCCH-PGMHBOJBSA-N [(z)-[5-chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate Chemical compound C12=CC=C(Cl)C=C2C(=N/OC(=O)C)/C(=O)N1CC1=CC(Cl)=CC=C1Cl OPQRFPHLZZPCCH-PGMHBOJBSA-N 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 239000002257 antimetastatic agent Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 238000012216 screening Methods 0.000 claims 8
- 206010027476 Metastases Diseases 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 210000004897 n-terminal region Anatomy 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 claims 3
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000013076 target substance Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050113101A KR100732298B1 (ko) | 2005-11-24 | 2005-11-24 | 유비키틴 c-말단 가수분해제-l1을 이용한 암전이 진단용조성물 |
| PCT/KR2006/004989 WO2007061256A1 (en) | 2005-11-24 | 2006-11-24 | Novel use of ubiquitin c-terminal hydrolase-l1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009517381A JP2009517381A (ja) | 2009-04-30 |
| JP2009517381A5 true JP2009517381A5 (enExample) | 2010-04-08 |
Family
ID=38067427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542245A Pending JP2009517381A (ja) | 2005-11-24 | 2006-11-24 | ユビキチンc末端ヒドロラーゼ−l1の新規な使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090208508A1 (enExample) |
| EP (1) | EP1993581A4 (enExample) |
| JP (1) | JP2009517381A (enExample) |
| KR (1) | KR100732298B1 (enExample) |
| CN (1) | CN101316605A (enExample) |
| WO (1) | WO2007061256A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009027349A2 (en) * | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| WO2010123365A1 (en) * | 2009-04-24 | 2010-10-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv) |
| KR101384642B1 (ko) * | 2012-06-22 | 2014-04-22 | 이화여자대학교 산학협력단 | N―말단이 제거된 유비퀴틴 c―말단 가수분해효소―l1(nt―uch―l1)를 유효성분으로 포함하는 파킨슨병 예방 및 치료용 약학적 조성물 |
| WO2014185561A1 (ko) * | 2013-05-13 | 2014-11-20 | 이화여자대학교 산학협력단 | 신규한 화합물 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 uch-l1 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2020110143A1 (en) | 2018-11-26 | 2020-06-04 | Rai Balwant | Methods, systems, and a kit for diagnosis, detection, monitoring and treatment of traumatic brain injury |
| CN110684740B (zh) * | 2019-08-09 | 2020-12-08 | 无锡傲锐东源生物科技有限公司 | 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用 |
| CN112891542B (zh) * | 2021-02-01 | 2021-11-16 | 暨南大学 | 一种包含UCHs抑制剂的药物组合物及其应用 |
| CN113970643B (zh) * | 2021-11-23 | 2023-06-30 | 北京大学人民医院 | 检测抗uch-l1表位的自身抗体的试剂在制备sle血清诊断相关产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69837529T2 (de) * | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| KR100545076B1 (ko) | 2003-01-27 | 2006-01-24 | 김현기 | 인간 원암유전자 hpp1 및 이에 의해 코드되는 단백질 |
| WO2004101762A2 (en) * | 2003-05-12 | 2004-11-25 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the colon |
| KR100520800B1 (ko) | 2003-05-19 | 2005-10-12 | 김진우 | 인간 원암유전자 pig2 및 이에 의해 코드되는 단백질 |
| JP2005272350A (ja) * | 2004-03-24 | 2005-10-06 | Vitamin C60 Bioresearch Kk | 癌転移阻害剤 |
-
2005
- 2005-11-24 KR KR1020050113101A patent/KR100732298B1/ko not_active Expired - Fee Related
-
2006
- 2006-11-24 JP JP2008542245A patent/JP2009517381A/ja active Pending
- 2006-11-24 EP EP06843893A patent/EP1993581A4/en not_active Withdrawn
- 2006-11-24 WO PCT/KR2006/004989 patent/WO2007061256A1/en not_active Ceased
- 2006-11-24 US US12/094,955 patent/US20090208508A1/en not_active Abandoned
- 2006-11-24 CN CNA2006800437290A patent/CN101316605A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526554A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| JP2014508298A5 (enExample) | ||
| JP2018049033A (ja) | リシルオキシダーゼ様2のアッセイおよびその使用の方法 | |
| JP2012501452A5 (enExample) | ||
| JP2009509517A (ja) | 肝細胞癌の分子マーカーおよびそれらの利用 | |
| WO2017039359A1 (ko) | 트립토파닐 티알엔에이 합성효소를 이용한 감염 질환 또는 감염 합병증의 진단용 조성물과 진단 마커 검출 방법 | |
| US20230417742A1 (en) | Improved assays to detect nucleosome modifications using antibody-targeted enzyme digestion | |
| JP2014503191A5 (enExample) | ||
| CN102459642A (zh) | 采用可检测蛋白质的细胞测定法 | |
| JP2009517381A5 (enExample) | ||
| Tyagi et al. | Detection of embryonic stem cell lysate biomarkers by surface plasmon resonance with reduced nonspecific adsorption | |
| JP2010535506A5 (enExample) | ||
| JP2011524002A (ja) | Ii型糖尿病のための血清マーカー | |
| An et al. | Detection of tyrosine hydroxylase in dopaminergic neuron cell using gold nanoparticles-based barcode DNA | |
| CN102947446B (zh) | 肺腺癌的预后预测方法、肺腺癌的检测试剂盒以及用于治疗肺腺癌的医药组合物 | |
| JP2010131022A5 (enExample) | ||
| EP2601528B1 (en) | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor | |
| Cao et al. | A novel method for precise detection of allergen‐specific IgE via immobilizing His‐tagged allergens to paper‐based device. | |
| CN116397020B (zh) | 生物标志物在预测磺酸类烷化剂诱导骨髓损伤敏感性中的应用 | |
| JP2005522228A5 (enExample) | ||
| KR20110096292A (ko) | 간암 진단용 마커로서의 socs6의 용도 | |
| KR20160050727A (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| WO2009150491A2 (en) | Interferon epsilon (ifne1) as a marker for targeted cancer therapy | |
| JP2012521745A5 (enExample) |